Results 121 to 130 of about 152,781 (323)

On contact graphs of paths on a grid [PDF]

open access: yesarXiv, 2018
In this paper we consider Contact graphs of Paths on a Grid (CPG graphs), i.e. graphs for which there exists a family of interiorly disjoint paths on a grid in one-to-one correspondence with their vertex set such that two vertices are adjacent if and only if the corresponding paths touch at a grid-point.
arxiv  

Targeting Antigen‐Presenting Cells to Enhance the Tumor‐Spleen Immunity Cycle through Liposome‐Neoantigen Vaccine

open access: yesAdvanced Science, EarlyView.
LNPsD18, a cationic liposome that enhances antigen‐presenting cell uptake in the spleen and tumor without targeting ligands is developed. Co‐delivering neoantigens and a TLR9 agonist significantly improve DC activation, tumor immunity, and survival in liver and colorectal cancer models, demonstrating the importance of dual‐site APC targeting for cancer
Yu Xu   +12 more
wiley   +1 more source

Antigen targeting to dendritic cells: Still a place in future immunotherapy?

open access: yesEuropean Journal of Immunology, Volume 52, Issue 12, Page 1909-1924, December 2022., 2022
Dendritic cell‐based immunotherapy is a promising vaccination strategy to treat infectious diseases, autoimmunity, and cancer. In this review, we present an overview on the current state of antigen targeting approaches via C‐type lectin receptors, with an outlook on future developments and potential for clinical translation.
Patrizia Stoitzner   +4 more
wiley   +1 more source

KK2DP7 Stimulates CD11b+ Cell Populations in the Spleen to Elicit Trained Immunity for Anti‐Tumor Therapy

open access: yesAdvanced Science, EarlyView.
This study introduces KK2DP7, a dendrimer‐structured peptide adjuvant, as a tool to decode trained immunity's role in antitumor therapy. Splenic CD11b+ cells mediate tumor suppression via TLR2‐IRF7 activation and epigenetic reprogramming, validated by adoptive transfer experiments.
Rui Zhang   +5 more
wiley   +1 more source

Flt3L, LIF, and IL‐10 combination promotes the selective in vitro development of ESAMlow cDC2B from murine bone marrow

open access: yesEuropean Journal of Immunology, Volume 52, Issue 12, Page 1946-1960, December 2022., 2022
In vitro culture of murine bone marrow cells in Flt3L + LIF + IL‐10 promotes CD11b+ ESAMlow cDC2B subset generation from CDP but blocks cDC1 and pDC development. Flt3L alone or combined does not induce cDC2A generation in vitro. Abstract The development of two conventional dendritic cells (DC) subsets (cDC1 and cDC2) and the plasmacytoid DC (pDC) in ...
Laura Cyran   +8 more
wiley   +1 more source

Engineered Genetic Circuits Activated by Bezafibrate Improve ESC‐Based TAA Cancer Vaccine Efficacy and PD‐L1 Nanobody Therapy

open access: yesAdvanced Science, EarlyView.
Synthetic gene circuits regulated by bezafibrate are developed to express tumor antigens and PD‐L1 nanobody (PD‐L1nb), enhancing cancer immunotherapy. Delivered via HEK293T cells, ESCs, or directly injected the plasmids containing the circuit into the tumor, the circuits reduce tumor growth, boost CD8+ T cells, and minimize T cell exhaustion.
Meiling Jin   +3 more
wiley   +1 more source

Oxalyl-CPG: a labile support for synthesis of sensitive oligonucleotide derivatives [PDF]

open access: green, 1991
Rushdi Alul   +3 more
openalex   +1 more source

STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
STING agonists show promise in preclinical studies in boosting an anti‐tumor response using the immune system. However, different limitations remain, and future research is needed to better understand how STING activation impacts the tumor microenvironment, identify effective combination strategies, and determine the best tumor types for STING agonist ...
Laura Gehrcken   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy